Literature DB >> 31415322

Immune Checkpoint Inhibitor Use in Sepsis: Monitoring Immune Checkpoint Inhibitor Toxicity.

Karthik Suresh1, Franco D'Alessio.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31415322      PMCID： PMC6738564          DOI： 10.1097/CCM.0000000000003813

Source DB:  PubMed          Journal:  Crit Care Med        ISSN： 0090-3493            Impact factor:   7.598


× No keyword cloud information.
  7 in total

1.  Immune Checkpoint Inhibition in Sepsis: A Phase 1b Randomized, Placebo-Controlled, Single Ascending Dose Study of Antiprogrammed Cell Death-Ligand 1 Antibody (BMS-936559).

Authors:  Richard S Hotchkiss; Elizabeth Colston; Sachin Yende; Derek C Angus; Lyle L Moldawer; Elliott D Crouser; Greg S Martin; Craig M Coopersmith; Scott Brakenridge; Florian B Mayr; Pauline K Park; June Ye; Ian M Catlett; Ihab G Girgis; Dennis M Grasela
Journal:  Crit Care Med       Date:  2019-05       Impact factor: 7.598

2.  Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors.

Authors:  Karthik Suresh; Khinh Ranh Voong; Bairavi Shankar; Patrick M Forde; David S Ettinger; Kristen A Marrone; Ronan J Kelly; Christine L Hann; Benjamin Levy; Josephine L Feliciano; Julie R Brahmer; David Feller-Kopman; Andrew D Lerner; Hans Lee; Lonny Yarmus; Franco D'Alessio; Russell K Hales; Cheng Ting Lin; Kevin J Psoter; Sonye K Danoff; Jarushka Naidoo
Journal:  J Thorac Oncol       Date:  2018-09-26       Impact factor: 15.609

3.  Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer.

Authors:  Jun Yeun Cho; Junghoon Kim; Jong Seok Lee; Yu Jung Kim; Se Hyun Kim; Yeon Joo Lee; Young-Jae Cho; Ho Il Yoon; Jae Ho Lee; Choon-Taek Lee; Jong Sun Park
Journal:  Lung Cancer       Date:  2018-09-18       Impact factor: 5.705

Review 4.  Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials.

Authors:  Monica Khunger; Sagar Rakshit; Vinay Pasupuleti; Adrian V Hernandez; Peter Mazzone; James Stevenson; Nathan A Pennell; Vamsidhar Velcheti
Journal:  Chest       Date:  2017-05-10       Impact factor: 9.410

5.  Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.

Authors:  Jarushka Naidoo; Xuan Wang; Kaitlin M Woo; Tunc Iyriboz; Darragh Halpenny; Jane Cunningham; Jamie E Chaft; Neil H Segal; Margaret K Callahan; Alexander M Lesokhin; Jonathan Rosenberg; Martin H Voss; Charles M Rudin; Hira Rizvi; Xue Hou; Katherine Rodriguez; Melanie Albano; Ruth-Ann Gordon; Charles Leduc; Natasha Rekhtman; Bianca Harris; Alexander M Menzies; Alexander D Guminski; Matteo S Carlino; Benjamin Y Kong; Jedd D Wolchok; Michael A Postow; Georgina V Long; Matthew D Hellmann
Journal:  J Clin Oncol       Date:  2016-09-30       Impact factor: 44.544

Review 6.  Clinical and biological heterogeneity in acute respiratory distress syndrome: direct versus indirect lung injury.

Authors:  Ciara M Shaver; Julie A Bastarache
Journal:  Clin Chest Med       Date:  2014-09-23       Impact factor: 2.878

Review 7.  Targeting Immune Cell Checkpoints during Sepsis.

Authors:  Naeem K Patil; Yin Guo; Liming Luan; Edward R Sherwood
Journal:  Int J Mol Sci       Date:  2017-11-14       Impact factor: 5.923
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.